Monte Rosa Therapeutics (GLUE) Set to Announce Quarterly Earnings on Thursday

Key Points

• Monte Rosa Therapeutics is expected to report Q3 2026 results before market open on Thursday, November 5. Analysts forecast a loss of $0.2396 per share and revenue of $33.87 million; the earnings call is scheduled for November 6 at 9:30 a.m. ET.
• The company missed expectations in its previous quarter, reporting a $0.43 per-share loss and $8.97 million in revenue versus estimates of $0.38 and $12.91 million, respectively. Analysts project full-year and next-year losses of $1.23 and $1.56 per share.
• GLUE shares opened at $10.85, well below their 52-week high of $25.77, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $26.67.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.2396) per share and revenue of $33.87 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The business had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million. On average, analysts expect Monte Rosa Therapeutics to post ($1.23) EPS for the current fiscal year and ($1.56) EPS for the next fiscal year.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock opened at $10.85 on Thursday. The business has a 50 day moving average price of $12.25 and a 200 day moving average price of $17.56. The company has a market capitalization of $925.65 million, a P/E ratio of -6.16 and a beta of 1.37. Monte Rosa Therapeutics has a 1 year low of $9.68 and a 1 year high of $25.77.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GLUE shares. Jefferies Financial Group restated a "buy" rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. Wedbush restated an "outperform" rating and issued a $27.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, September 9th. Benchmark reaffirmed a "buy" rating on shares of Monte Rosa Therapeutics in a research note on Monday, October 5th. UBS Group began coverage on Monte Rosa Therapeutics in a report on Sunday, October 11th. They issued a "buy" rating and a $19.00 target price on the stock. Finally, Raymond James Financial set a $25.00 price objective on Monte Rosa Therapeutics in a research note on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Monte Rosa Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $26.67.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell's natural protein-degradation machinery. The company's approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.

Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.